Peter Andersen
YOU?
Author Swipe
View article: Insulin stimulated upregulation of OCTN2 carnitine transporters is impaired in patients with Primary carnitine deficiency
Insulin stimulated upregulation of OCTN2 carnitine transporters is impaired in patients with Primary carnitine deficiency Open
Background: Primary carnitine deficiency (PCD) is an autosomal recessive disorder characterized by a lack of functional carnitine transporters OCTN2 (Organic Cation/Carnitine Transporter 2), which has been linked to several cases of sudden…
View article: <scp>M</scp> et <scp>ALD</scp> : Diagnosis and Prognosis With Non‐Invasive Tests
<span>M</span> et <span>ALD</span> : Diagnosis and Prognosis With Non‐Invasive Tests Open
Background Non‐invasive tests (NITs) are central to diagnosing and stratifying risk in steatotic liver disease (SLD). However, it remains unclear whether guideline‐recommended NIT cut‐offs apply to metabolic and alcohol‐related liver disea…
View article: Prevalence, severity and determinants of steatotic liver disease among individuals with metabolic and alcohol risk from the community
Prevalence, severity and determinants of steatotic liver disease among individuals with metabolic and alcohol risk from the community Open
GOV: NCT03308916.
View article: The postbiotic ReFerm® versus standard nutritional support in advanced alcohol-related liver disease (GALA-POSTBIO): a randomized controlled phase 2 trial
The postbiotic ReFerm® versus standard nutritional support in advanced alcohol-related liver disease (GALA-POSTBIO): a randomized controlled phase 2 trial Open
Impaired gut barrier function may lead to progression of liver fibrosis in people with alcohol-related liver disease. The postbiotic ReFerm® can lower gut barrier permeability and may thereby reduce fibrosis formation. Here, we report the …
View article: Steatotic Liver Disease Classification Is Dynamic, Affecting Clinical Trial Eligibility and Subclass-Specific Treatments
Steatotic Liver Disease Classification Is Dynamic, Affecting Clinical Trial Eligibility and Subclass-Specific Treatments Open
SLD and the subclassification hereof is highly dynamic, especially driven by changes in alcohol use and hepatic steatosis. This affects eligibility for clinical trials and clinical management of patients with SLD.
View article: UNDERSTANDING THE IMMUNE LANDSCAPE OF ALCOHOL-RELATED LIVER DISEASE THROUGH FIBRO-INFLAMMATORY SEROLOGICAL BIOMARKERS
UNDERSTANDING THE IMMUNE LANDSCAPE OF ALCOHOL-RELATED LIVER DISEASE THROUGH FIBRO-INFLAMMATORY SEROLOGICAL BIOMARKERS Open
View article: Quantification of alcohol intake in patients with steatotic liver disease and excessive alcohol intake
Quantification of alcohol intake in patients with steatotic liver disease and excessive alcohol intake Open
View article: Using liver stiffness to predict and monitor the risk of decompensation and mortality in patients with alcohol-related liver disease
Using liver stiffness to predict and monitor the risk of decompensation and mortality in patients with alcohol-related liver disease Open
Patients at risk of alcohol-related liver disease (ALD) are at significant risk of progressive disease and adverse outcomes. Monitoring is essential for optimal disease surveillance and patient guidance, but non-invasive monitoring tools a…
View article: Infections increase the risk of decompensation and death in patients with early alcohol-related liver disease
Infections increase the risk of decompensation and death in patients with early alcohol-related liver disease Open
This study reveals that infections significantly worsen the prognosis of patients with early alcohol-related liver disease (ALD), increasing the likelihood of decompensation and death by up to eight times. These findings, pertinent to heal…
View article: LiverPRO for the Prediction of Significant Liver Fibrosis in Primary Care: Development, Validation, and Prognostic Evaluation of a Novel Score
LiverPRO for the Prediction of Significant Liver Fibrosis in Primary Care: Development, Validation, and Prognostic Evaluation of a Novel Score Open
View article: Screening for Fibrosis Promotes Lifestyle Changes: A Prospective Cohort Study in 4796 Individuals
Screening for Fibrosis Promotes Lifestyle Changes: A Prospective Cohort Study in 4796 Individuals Open
Screening for liver fibrosis is associated with sustained improvements in alcohol consumption, diet, weight, and exercise in at-risk ALD and MASLD. The changes are most pronounced in screening positive participants but not limited to this …
View article: Development, validation, and prognostic evaluation of a risk score for long-term liver-related outcomes in the general population: a multicohort study
Development, validation, and prognostic evaluation of a risk score for long-term liver-related outcomes in the general population: a multicohort study Open
View article: From Genesis to Gottfried’s Tristan: Peace Trees in Medieval German Texts and their Latin and French Sources
From Genesis to Gottfried’s Tristan: Peace Trees in Medieval German Texts and their Latin and French Sources Open
View article: Vorwort
Vorwort Open
View article: Validation of scores of <scp>PRO‐C3</scp> to predict liver‐related events in alcohol‐related liver disease
Validation of scores of <span>PRO‐C3</span> to predict liver‐related events in alcohol‐related liver disease Open
Background and Aims Risk prediction in alcohol‐related liver disease (ArLD) is an unmet need. We aimed to assess PRO‐C3 models to predict liver‐related events (LRE) in patients with a history of excessive alcohol use without an established…
View article: Using the ELF test, FIB-4 and NAFLD fibrosis score to screen the population for liver disease
Using the ELF test, FIB-4 and NAFLD fibrosis score to screen the population for liver disease Open
Clinicaltrials.gov number NCT03308916.
View article: Rifaximin-α for liver fibrosis in patients with alcohol-related liver disease (GALA-RIF): a randomised, double-blind, placebo-controlled, phase 2 trial
Rifaximin-α for liver fibrosis in patients with alcohol-related liver disease (GALA-RIF): a randomised, double-blind, placebo-controlled, phase 2 trial Open
The EU Horizon 2020 Research and Innovation Program and The Novo Nordisk Foundation.
View article: Sphingolipids Are Depleted in Alcohol-Related Liver Fibrosis
Sphingolipids Are Depleted in Alcohol-Related Liver Fibrosis Open
View article: Björn Reich (éd.) : Straßburger Kartenlosbuch | Marco Heiles, Björn Reich, Matthias Standke (éd.) : Gedruckte deutsche Losbücher des 15. und 16. Jahrhunderts
Björn Reich (éd.) : Straßburger Kartenlosbuch | Marco Heiles, Björn Reich, Matthias Standke (éd.) : Gedruckte deutsche Losbücher des 15. und 16. Jahrhunderts Open
Le présent compte rendu porte sur deux volumes étroitement liés par leur thématique. Ils constituent les deux premiers numéros d’une nouvelle collection, Ludica, consacrée aux jeux historiques et créée par Marco Heiles et Björn Reich, coll…
View article: THE EFFECT OF REFERM VERSUS FRESUBIN ON HEPATIC STELLATE CELL ACTIVITY IN PATIENTS WITH ADVANCED ALCOHOL-RELATED LIVER DISEASE: A 24 WEEK RANDOMIZED CONTROLLED TRIAL
THE EFFECT OF REFERM VERSUS FRESUBIN ON HEPATIC STELLATE CELL ACTIVITY IN PATIENTS WITH ADVANCED ALCOHOL-RELATED LIVER DISEASE: A 24 WEEK RANDOMIZED CONTROLLED TRIAL Open
View article: LiverScreen project: study protocol for screening for liver fibrosis in the general population in European countries
LiverScreen project: study protocol for screening for liver fibrosis in the general population in European countries Open
View article: Association of the Liver and Plasma Lipidomes with the Histological Stage of Alcohol-Related Liver Disease
Association of the Liver and Plasma Lipidomes with the Histological Stage of Alcohol-Related Liver Disease Open
Background and aims Alcohol disturbs hepatic lipid synthesis and transport, but the role of lipid dysfunction in the severity of alcohol-related liver disease (ALD) is unclear. We therefore characterised the liver and plasma lipidome in a …